Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baidu
BIDU
|
+$462M |
| 2 |
AGN
Allergan plc
AGN
|
+$390M |
| 3 |
AT&T
T
|
+$371M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$353M |
| 5 |
NextEra Energy
NEE
|
+$326M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$1.97B |
| 2 |
Meta Platforms (Facebook)
META
|
+$435M |
| 3 |
Pfizer
PFE
|
+$377M |
| 4 |
GE Aerospace
GE
|
+$354M |
| 5 |
Starbucks
SBUX
|
+$323M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.43% |
| 2 | Technology | 12.71% |
| 3 | Consumer Staples | 9.79% |
| 4 | Financials | 8.2% |
| 5 | Utilities | 8.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2351
Agree Realty
ADC
$9.41B
| $1.16M | ﹤0.01% |
18,800
-26,000
| -58% | -$1.85M |
|
|
INFI
2352
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $1.16M | ﹤0.01% |
1,385,414
+127,101
| +10% | +$147K |
|
|
PW
2353
Power REIT
PW
$2.84M
| $1.16M | ﹤0.01% |
11,120
+1,464
| +15% | +$148K |
|
2354
CB Financial Services
CBFV
$193M
| $1.16M | ﹤0.01% |
59,998
-3,643
| -6% | -$98.5K |
|
|
PROF
2355
Profound Medical
PROF
$269M
| $1.16M | ﹤0.01% |
120,180
+107,280
| +832% | +$1.39M |
|
|
SSKN
2356
DELISTED
Strata Skin Sciences
SSKN
| $1.16M | ﹤0.01% |
121,685
+5,719
| +5% | +$94.4K |
|
2357
Viasat
VSAT
$11.1B
| $1.16M | ﹤0.01% |
32,193
-89,400
| -74% | -$5.16M |
|
|
AGEN
2358
Agenus
AGEN
$290M
| $1.15M | ﹤0.01% |
23,933
+4,493
| +23% | +$282K |
|
|
ADMS
2359
DELISTED
Adamas Pharmaceuticals
ADMS
| $1.15M | ﹤0.01% |
398,380
+105,600
| +36% | +$473K |
|
2360
Hope Bancorp
HOPE
$1.79B
| $1.15M | ﹤0.01% |
139,900
-448,164
| -76% | -$5.6M |
|
2361
PCB Bancorp
PCB
$392M
| $1.14M | ﹤0.01% |
116,832
-3,500
| -3% | -$48.3K |
|
|
SIOX
2362
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $1.14M | ﹤0.01% |
468,123
+147,700
| +46% | +$533K |
|
2363
Cue Biopharma
CUE
$114M
| $1.14M | ﹤0.01% |
2,680
+1,234
| +85% | +$598K |
|
2364
Blue Owl Capital
OBDC
$5.74B
| $1.14M | ﹤0.01% |
+98,600
| New | +$1.44M |
|
2365
iShares 20+ Year Treasury Bond ETF
TLT
$41.7B
| $1.14M | ﹤0.01% |
+6,900
| New | +$1.03M |
|
2366
Curis
CRIS
$7.83M
| $1.14M | ﹤0.01% |
4,031
+185
| +5% | +$98.2K |
|
2367
Vanguard Morningstar Total Stock Market ETF
VTI
$684B
| $1.13M | ﹤0.01% |
8,800
-1,500
| -15% | -$232K |
|
2368
Innospec
IOSP
$2.28B
| $1.13M | ﹤0.01% |
16,300
-700
| -4% | -$63.9K |
|
2369
Columbia Banking Systems
COLB
$8.84B
| $1.13M | ﹤0.01% |
+42,106
| New | +$1.48M |
|
2370
Vanguard Morningstar Growth ETF
VUG
$231B
| $1.13M | ﹤0.01% |
+43,140
| New | +$1.29M |
|
|
TUES
2371
DELISTED
Tuesday Morning Corp
TUES
| $1.13M | ﹤0.01% |
1,957,690
+147,739
| +8% | +$211K |
|
|
AIOS
2372
AIOS Tech
AIOS
$39M
| $1.12M | ﹤0.01% |
739
-406
| -35% | -$555K |
|
2373
Protalix BioTherapeutics
PLX
$198M
| $1.12M | ﹤0.01% |
477,434
+17,800
| +4% | +$58.9K |
|
|
APTX
2374
DELISTED
Aptinyx Inc. Common Stock
APTX
| $1.12M | ﹤0.01% |
518,929
+211,279
| +69% | +$691K |
|
2375
iShares 0-5 Year TIPS Bond ETF
STIP
$15.8B
| $1.12M | ﹤0.01% |
11,200
-9,800
| -47% | -$985K |
|
Similar funds
Renaissance Technologies's Q1 2020 Portfolio in Review
As of Q1 2020, Renaissance Technologies held 4,047 positions worth $103B, down 21% from $130B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Renaissance Technologies's Q1 2020 filing shows 573 new, 1,474 increased, 1,328 reduced and 645 closed positions. Its largest new stake was AT&T: 13,563,699 shares worth $299M. The largest sale was Tesla, an estimated $1.97B.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 21% a quarter earlier, followed by Technology and Consumer Staples.
- Renaissance Technologies's largest Q1 2020 buy was AT&T: 13,563,699 shares worth $299M.
- Renaissance Technologies added most to Baidu in Q1 2020, an estimated $462M increase.
- Renaissance Technologies's biggest Q1 2020 reduction was Tesla, cutting an estimated $1.97B.
- Renaissance Technologies fully exited Phillips 66 in Q1 2020, selling an estimated $214M.
- Renaissance Technologies's ten largest holdings make up 15% of its $103B portfolio in Q1 2020.
- Renaissance Technologies opened 573 new positions and closed 645 in Q1 2020.
- Renaissance Technologies's portfolio value fell 21% quarter-over-quarter to $103B.
Based on Renaissance Technologies's 13F filing for Q1 2020, filed 14 May 2020.